The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.

Jakob M. Riedl,Florian Posch,Gerald W. Prager,Wolfgang Eisterer,Leopold Oehler,Thamer Sliwa,Klaus Wilthoner,Andreas L. Petzer,P Pichler,Eva Hubmann,Thomas Winder,Sonja Burgstaller,Markus Korger,Johannes Andel,Richard Greil,Hans-Joerg Neumann,Martin Pecherstorfer,Kathrin Philipp-Abbrederis,Angela Djanani,Birgit Gruenberger,F. Laengle,Ewald Wöll,Armin Gerger

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.

2020

Background:The pretreatment De Ritis ratio [aspartate transaminase (AST)/alanine transaminase (ALT)] has been shown to be an adverse prognostic marker in various cancer entities. However, its relev...

Keywords:

Cancer
Pancreatic cancer
Aspartate transaminase
Gemcitabine
Nab-paclitaxel
Pharmacology
Post-hoc analysis
Biomarker (medicine)
Medicine
Gastroenterology
Internal medicine
Alanine transaminase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations